Center for Addiction Medicine

A. Eden Evins, MD, MPH

Eden Evins Square

Founding Director MGH Center for Addiction Medicine and Cox Family Professor of Psychiatry in the field of Addiction Medicine at Harvard Medical School

Contact:    aeevins@mgh.harvard.edu    (617) 643-4679

 

Dr. Evins is a clinically trained psychiatrist with consecutive funding since 1999 as PI on NIDA funded projects to conduct studies of efficacy of pharmacotherapeutic cessation aids in smokers with and without serious mental illness, of the effect of nicotine on cognitive performance in those with and without schizophrenia, of behavioral, physiologic, and fMRI ascertained assessments of impulsivity, risk taking, reactivity to drug-related cues and the relationship between cue reactivity and relapse to drug use, and a newer line of investigation into the effect of cannabis on neural markers of reward and social influence, psychiatric symptoms, cognitive function, and addictive behaviors and of the impact of different maintenance treatments for opiate use disorder on relapse and cognitive functioning. Dr. Evins is an international expert in co-occurring substance dependence and psychiatric illness, with landmark work in treatment of nicotine dependence among those with schizophrenia and bipolar disorder. Dr. Evins brings invaluable expertise in conduct of clinical treatment trials in those with psychiatric (particular schizophrenia and bipolar disorder) and substance use (particularly nicotine, cannabis and opiate use disorders) to the mentor team of the K12. She has conducted large, multi-center clinical studies in addition to and often integrated with laboratory based and neuroimaging studies. She serves as the Cox Family Professor of Psychiatry in the Field of Addiction Medicine, as the Founding Director of the MGH Center for Addiction Medicine, as Director of the MGH Addiction Research Program, and as MGH site director for the Harvard Addiction Fellowship Program that provides clinical specialty training to 3 addiction psychiatrists per year. In the course of this work, she has gained considerable administrative expertise in the critical issues of standardized assessment, project feasibility, regulatory aspects of clinical research, ethical conduct of clinical research, human subjects protection, and practical issues of staffing, recruitment, budgeting, and communication. She has a track record of completing studies and producing several peer-reviewed publications from each project. She has built an extensive track record of successful mentorship of junior investigators in patient oriented addiction research who are now clinical and research leaders. Her goal is to assist junior investigators with a range of backgrounds and interests, including 1) investigators with a primary focus on patient-oriented addiction research; 2) investigators from other specialties (e.g., medicine, pharmacology, neuroscience, neuropsychology), who seek to integrate addiction research into their specific fields, and 3) investigators working in related fields who can benefit from her knowledge and experience.

Her primary goal in mentoring residents, post-doctoral fellows and junior faculty is to foster their independent research. She has worked closely with Dr. Rigotti since 2001, and they have co-mentored trainees. She devotes significant professional time to mentorship of the next generation of patient oriented addiction researchers.

 

Current Projects

Advancing a novel portable detection method for cannabis intoxication

NIDA R42 DA 043977 2017-20

Fast Track Small Business Technology Transfer Award

 

 

Medical marijuana, neurocognition, and subsequent substance use

NIDA R01DA042043  2016-21

This study will use a randomized controlled trial design to test whether medical marijuana patients experience unintended negative consequences from medical marijuana use such as progression to addiction, neurocognitive impairments, and brain-based changes. The resulting data will inform clinicians, scientists, and policy-makers about unforeseen effects and potential outcomes of medical marijuana policies.

 

Dissemination of effective smoking cessation treatment to smokers with serious mental illness

PCORI PCS-1504-30472 2016-21

A large pragmatic trial with cluster randomized design to determine whether academic detailing to primary care providers and health outreach worker support to patients and providers will improve smoking cessation rates in people with SMI.

 

Reduced nicotine cigarettes in smokers with mood and anxiety disorders

NIH 4P50DA036107   2013-18

The aim of this study is to evaluate the effect of progressive nicotine reduction in cigarettes on smoking behavior in smokers with mood and anxiety disorders.

 

Trial of integrated smoking cessation, exercise and weight management in SMI

NIMH 5R01MH104553 2014-19

This trial will test the hypothesis that an 18-month CVD risk reduction program consisting of smoking cessation treatment, diet and exercise will improve cardiovascular health in persons with serious mental illness.

 

Comprehensive CVD risk reduction trial in persons with serious mental illness

NHLBI 4R01HL112299 2013-18

This trial will test the hypothesis that an 18-month CVD risk reduction program consisting of a heart health coach to provide individual CVD risk reduction behavioral counseling, coordination with primary care providers to manage risk factors (e.g., hypertension), and collaboration with mental health staff and social supports will improve cardiovascular health in persons with SMI.

 

Integrated behavioral diabetes management for individuals with serious mental illness

MGH Executive Office on Community Health Community Health (ECOCH)/Health Equity Grant

2016-18

The primary aim of this project is to evaluate the efficacy and feasibility of a behavioral diabetes intervention integrated into the psychiatric care for adults with serious mental illness.

 

Mentoring in addiction treatment research

NIDA 2K24DA030443 2011-21

This K award will support mentoring activities in addiction treatment research with salary support for Dr. Evins and statistical support staff.

 

 

Career development program in substance use and addiction medicine

NIDA 1K12DA043490 2017-22

The goal of this Mentored Award is to develop a multidisciplinary program at the Massachusetts General Hospital that will support intensive, mentored training and career development of promising post-doctoral clinician-scientists who aim to establish independent research programs in patient oriented addiction research.

 

 

 

%d bloggers like this: